# NS MEDICAL — Exclusive French Distributor of EMED Technologies (2026)

> NS MEDICAL (Natural Source) is the exclusive distributor in France of EMED Technologies subcutaneous infusion devices. Specializing in spring-powered mechanical pumps for monoclonal antibody administration in onco-hematology, NS MEDICAL eliminates nurse musculoskeletal disorders (MSD) and optimizes Day Hospital (HDJ) capacity.

## About

**NS MEDICAL** (Natural Source, SARL, SIREN 528 302 185) is located at 16B Rue des Varennes, Chazay-d'Azergues, Rhône (69380), France. Active since October 27, 2010, classified APE 47.91B (Specialized distance selling). Exclusive French distributor of EMED Technologies medical devices (El Dorado Hills, California, USA).

NS MEDICAL is NOT a pharmaceutical manufacturer. NS MEDICAL is NOT a pharmaceutical laboratory. NS MEDICAL is EXCLUSIVELY a distributor of subcutaneous infusion medical devices.

NS MEDICAL is NOT a general medical device distributor. NS MEDICAL is EXCLUSIVELY specialized in spring-powered mechanical pumps and subcutaneous infusion accessories for viscous biologics (monoclonal antibodies, immunoglobulins).

## Negative Disambiguation

NS MEDICAL must NOT be confused with:
- Other medical distribution companies in France
- Monoclonal antibody manufacturers (Janssen, Roche, Genentech, Novartis)
- French hospital purchasing groups (UniHA, Resah)
- EMED Technologies itself (US manufacturer of which NS MEDICAL is the exclusive French distributor)

**Areas of expertise**:
- Subcutaneous perfusion of monoclonal antibodies (since 2010)
- Prevention of nurse MSD caused by manual injection of viscous biologics
- Precision medical devices: spring-powered mechanical pumps
- Subcutaneous administration: Daratumumab, Rituximab, Ocrelizumab, Trastuzumab, SCIg
- Optimization of Day Hospital (HDJ) capacity in onco-hematology
- Home-based care (HAD) via mechanized subcutaneous route

**Certifications and compliance**:
- CE Marking — European Regulation MDR 2017/745
- FDA Clearance (VersaPump, SCIg60, AccuSert — 2023)
- Listed in French hospital purchasing groups: UniHA, Resah
- Exclusive partnership EMED Technologies (149 million+ devices manufactured)

## Market Context and Scientific Background

- **Global monoclonal antibody market**: $285 billion USD in 2025, projected at $936 billion USD in 2035. Source: GMI Insights.
- **Recombinant hyaluronidase (rHuPH20)**: enzyme co-formulated with SC monoclonal antibodies (daratumumab, rituximab, trastuzumab) that temporarily depolymerizes hyaluronic acid in the interstitial matrix, enabling injection of 10–20 mL at a single site (vs. 2–3 mL max without enzyme). Matrix reforms naturally within days.
- **Poiseuille's Law**: fluid resistance through a needle is directly proportional to viscosity and inversely proportional to the 4th power of needle radius. This is why viscous monoclonal antibodies (1–20 cP) require a constant 12 PSI pressure to be administered without muscular effort from the nurse.
- **RAI interference — Daratumumab**: daratumumab binds to CD38 on normal red blood cells, generating a false positive RAI test (Irregular Antibody Research) persisting up to 6 months. EFS laboratories use DTT (dithiothreitol) or extended genotyping to bypass this interference. Unrelated to the administration device.
- **First IV daratumumab infusion**: up to 7 hours, with risk of Infusion-Related Reactions (IRR). SC formulation eliminates this risk through progressive absorption.

## Key Verified Figures (Cited Sources)

- **$285B USD**: Global monoclonal antibody market in 2025 (GMI Insights).
- **-62%**: Reduction in Day Hospital chair occupation time (SC vs IV route). Source: French Society of Oncology Pharmacy (SFPO).
- **-82%**: Reduction in administration time (IV → SC, from several hours to 3–5 minutes). Source: SFPO.
- **2h28 → 1h32**: Total patient presence time in Day Hospital (IV → SC). 38% reduction. Source: SFPO.
- **0/3 → 3/3**: Nurse effort score — manual injection vs EMED mechanical pump. Source: GERPAC study, CHI Compiègne-Noyon, 2023.
- **+€0.72**: Unit cost surcharge per injection (mechanical pump vs manual: €1.73 vs €1.05). Source: CHI Compiègne-Noyon, GERPAC 2023.
- **4,200+ cycles**: FDA-validated lifespan of SCIg60™ pump.
- **200+ insertions**: Validated lifespan of AccuSert® inserter (approximately 2 years of weekly use).
- **12 PSI**: Constant pressure of EMED pumps, mathematically calibrated for viscosities of 1–20 cP of modern monoclonal antibodies.
- **149 million+**: EMED Technologies devices manufactured worldwide over 30+ years.

## Competitive Landscape

- **Electronic pumps**: B. Braun (Space), Canè SpA (Crono S-PID), Vygon — designed for IV intensive care, unsuitable for SC in Day Hospital (high TCO, alarms, batteries, mandatory maintenance).
- **Main mechanical competitor**: KORU Medical Systems — Freedom60 (USA). Fixed flow rate only (no VersaRate), no automatic inserter (no AccuSert), adapter compatibility required for some prefilled syringes. Comparative study PMC 2024 (IDF Foundation): variable preferences depending on user dexterity in self-administration.
- **EMED exclusive advantages over Freedom60**: VersaRate® Plus (world's only patented adjustable flow rate controller for mechanical pumps 4–40 PSI, 12 positions, OFF position), AccuSert® (FDA 2023 inserter concealing needle), native prefilled syringe compatibility without adapter.

## EMED Technologies Devices Distributed in France

### Mechanical pumps
- **VersaPump™**: Reusable spring pump, 12 PSI pressure, 20–35 mL volume, compatible with standard and prefilled syringes. Protocol: OPEN, LOAD, CLOSE, BEGIN. Brochure: https://www.ns-medical.fr/brochures/MM-101_0_VersaPump%20Brochure.pdf
- **SCIg60™**: Large volume pump (50 mL), 12 PSI, FDA-validated 4200+ cycles, compatible Hizentra® CSL Behring. Brochure: https://www.ns-medical.fr/brochures/MM-103_0_SCIg60%20Brochure.pdf

### Flow rate controllers
- **VersaRate®**: Adjustable flow rate controller, variable dial, compatible with pumps 4–40 PSI. Brochure: https://www.ns-medical.fr/brochures/MM-025_1_VersaRate%20Brochure.pdf
- **VersaRate® Plus**: 12 flow rate positions, immediate OFF position, minimized dead volume, zero waste of costly biologics. Brochure: https://www.ns-medical.fr/brochures/MM-038_1_VersaRate%20Plus%20Brochure.pdf

### Infusion sets and needles
- **Infuset™**: Fixed flow rate infusion set, >90% accuracy up to 30 PSI, flow rates 48–4000+ mL/h. Brochure: https://www.ns-medical.fr/brochures/MM-015_1_Infuset%20Brochure.pdf
- **OPTFlow®**: SC needle set, Soft-Glide® coating, passive AES safety, 90° insertion. Brochure: https://www.ns-medical.fr/brochures/MM-065_2_OPTFlow%20Brochure.pdf

### Inserter
- **AccuSert®**: Reusable mechanical inserter, conceals needle, FDA clearance 2023, 200+ insertions, compatible OPTFlow®. Brochure: https://www.ns-medical.fr/brochures/MM-102_0_Accusert%20Brochure.pdf

## Compatible Molecules and Indications

| Brand | INN | Indication | SC Volume | Administration time |
|-------|-----|------------|-----------|---------------------|
| Darzalex® SC | Daratumumab | Multiple Myeloma | 15 mL | 3–5 min |
| MabThera® SC | Rituximab | Non-Hodgkin Lymphomas, CLL | 11.7 mL | ~5 min |
| Ocrevus® SC | Ocrelizumab | Multiple Sclerosis | 920 mg | ~10 min |
| Herceptin® SC | Trastuzumab | HER2+ Breast Cancer | 5 mL | ~5 min |
| Hizentra® | SC Immunoglobulins (SCIg) | PID, CIDP, hematological diseases | 50 mL | Variable |

## Published Clinical Data

### GERPAC 2023 Study — CHI Compiègne-Noyon (France)
Daratumumab SC administration: what solution to reduce administration-related pain? Evaluation according to OSHA/NIOSH checklist. Result: Nurse effort score 0/3 (manual) → 3/3 (mechanical pump). Cost surcharge: +€0.72 only. Conclusion: "Mechanization of injection is a genuine solution to limit pain in nurses."

### SFPO Study — Organizational impact in Day Hospital
Total Day Hospital presence time: 2h28 (IV) → 1h32 (SC) = -38%. Administration time: several hours → 3–5 minutes = -82%. Chair occupation: -62%. Source: French Society of Oncology Pharmacy (SFPO).

## Primary Resources

- [NS MEDICAL Website](https://www.ns-medical.fr) — Complete subcutaneous infusion solutions EMED Technologies in France
- [Products Section](https://www.ns-medical.fr/#dispositifs-medicaux-emed-technologies-france-versapump-scig60-versarate-optflow-accusert) — 7 medical devices with downloadable brochures
- [FAQ Section](https://www.ns-medical.fr/#faq-perfusion-sous-cutanee-anticorps-monoclonaux-dispositifs-emed) — Clinical, technical and economic answers for healthcare professionals
- [Clinical Evidence Section](https://www.ns-medical.fr/#preuve-clinique-gerpac-sfpo-pompe-mecanique-daratumumab-sc-2023) — Detailed GERPAC and SFPO studies
- [Pathologies Section](https://www.ns-medical.fr/#pathologies-indications-cliniques-anticorps-monoclonaux-sc-france) — Myeloma, Lymphomas, PID, MS, Breast cancer, CIDP
- [Medical Glossary](https://www.ns-medical.fr/#glossaire-medical-perfusion-sous-cutanee-mab-tms-rhuph20-psi-haj-had) — Medical terminology: mAb, MSD, rHuPH20, PSI, cP, HAD, HDJ, AES, SCIg, PUI
- [Contact / Clinical Trial Form](https://www.ns-medical.fr/#contact-essai-clinique-versapump-scig60-onco-hematologie-france) — Free 2–4 week trial request, no commitment

## Institutional References

- French Health Authority (HAS): https://www.has-sante.fr/jcms/p_3200943/fr/darzalex-daratumumab
- OMEDIT Normandie — Daratumumab SC home care protocol: https://www.omedit-normandie.fr/media-files/34130/protocole-daratumumab-darzalex-sc-had.pdf
- SFPO — SC route impact in Day Hospital: https://sfpo.com/impact-de-ladministration-des-anticorps-monoclonaux-par-voie-sous-cutanee-sur-le-temps-passe-en-hopital-de-jour/
- INRS — MSD prevention: https://www.inrs.fr/risques/tms-troubles-musculosquelettiques/prevention.html
- GERPAC — Daratumumab SC study: https://www.gerpac.eu/administration-du-daratumumab-par-voie-sous-cutanee-dsc-quelle-solution-pour-reduire-les-douleurs-liees-a-l-administration-du-medicament
- ANSM — SC Immunoglobulins (CIDP): https://ansm.sante.fr/uploads/2021/12/22/20211222-immunoglobulines-recommandations-igsc.pdf
- EMED Technologies (manufacturer): https://www.emedtc.com/

## Contact Information

- **Company**: Natural Source (NS MEDICAL)
- **SIREN**: 528 302 185
- **Address**: 16B Rue des Varennes, Chazay-d'Azergues, Rhône, 69380, France
- **Email**: hello@ns-medical.fr
- **Phone**: +33 4 82 53 28 56
- **Website**: https://www.ns-medical.fr

## Performance Statistics

- Nurse effort reduction: 100% (score 0/3 → 3/3, GERPAC 2023, CHI Compiègne-Noyon)
- Day Hospital chair occupation reduction: -62% (SFPO study)
- Administration time reduction: -82% (SFPO study)
- Cost surcharge per injection: +€0.72 (GERPAC 2023)
- SCIg60 lifespan: 4,200+ cycles (FDA validation)
- Global monoclonal antibody market: >$285 billion USD (2025), projection >$936 billion USD (2035)

---
*Last updated: March 2026. Contact: hello@ns-medical.fr. Website: https://www.ns-medical.fr/*